Patents by Inventor Yong Woon Choi

Yong Woon Choi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical formulation comprising anti-EGFR antibody
    Patent number: 10918717
    Abstract: The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: February 16, 2021
    Assignee: GREEN CROSS CORPORATION
    Inventors: Yong Woon Choi, Yoo Hoon Kim, Jungsub Choi
  • Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
    Patent number: 10174299
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter Syndrome.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: January 8, 2019
    Assignees: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF
    Publication number: 20180112199
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter Syndrome.
    Type: Application
    Filed: November 14, 2017
    Publication date: April 26, 2018
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
    Patent number: 9896672
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: February 20, 2018
    Assignees: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • PHARMACEUTICAL FORMULATION COMPRISING ANTI-EGFR ANTIBODY
    Publication number: 20170368175
    Abstract: The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.
    Type: Application
    Filed: January 15, 2016
    Publication date: December 28, 2017
    Applicant: GREEN CROSS CORPORATION
    Inventors: Yong Woon CHOI, Yoo Hoon KIM, Jungsub CHOI
  • COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF
    Publication number: 20160326504
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Application
    Filed: June 16, 2016
    Publication date: November 10, 2016
    Applicants: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu JIN, Yo Kyung CHUNG, Sang Hoon PAIK, Yoo Chang PARK, Jinwook SEO, Yong Woon CHOI, Jong Mun SON, Yong-Chul KIM
  • COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF
    Publication number: 20160145589
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Application
    Filed: December 21, 2015
    Publication date: May 26, 2016
    Applicants: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
    Patent number: 9249397
    Abstract: Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: February 2, 2016
    Assignees: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
    Patent number: 9206402
    Abstract: Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: December 8, 2015
    Assignees: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF
    Publication number: 20150320843
    Abstract: Disclosed are a composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for treating Hunter syndrome. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Application
    Filed: July 27, 2015
    Publication date: November 12, 2015
    Applicants: MEDIGENEBIO CORPORATION, GREEN CROSS CORPORATION
    Inventors: Thong-Gyu JIN, Yo Kyung CHUNG, Sang Hoon PAIK, Yoo Chang PARK, Jinwook SEO, Yong Woon CHOI, Jong Mun SON, Yong-Chul KIM
  • COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF
    Publication number: 20140242059
    Abstract: Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Application
    Filed: June 15, 2012
    Publication date: August 28, 2014
    Applicants: MEDIGENEBIO CORPORATION, GREEN CROSS CORPORATION
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim